CAMBRIDGE, MA, CREATE Medicines, a clinical-stage biotechnology company pioneering in vivo immune programming, today announced the closing of its $122 million Series B funding round.
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.